Carta Acesso aberto Revisado por pares

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

2022; Massachusetts Medical Society; Volume: 386; Issue: 13 Linguagem: Inglês

10.1056/nejmc2200133

ISSN

1533-4406

Autores

Heba N. Altarawneh, Hiam Chemaitelly, Mohammad R. Hasan, Houssein H. Ayoub, Suelen H. Qassim, Sawsan AlMukdad, Peter Coyle, Hadi M. Yassine, Hebah A. Al-Khatib, Fatiha M. Benslimane, Zaina Al Kanaani, Einas Al Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al‐Kuwari, Adeel A. Butt, Hamad Eid Al‐Romaihi, Mohamed H. Al‐Thani, Abdullatif Al‐Khal, Roberto Bertollini, Patrick Tang, Laith J. Abu‐Raddad,

Tópico(s)

COVID-19 Clinical Research Studies

Resumo

InfectionTo the Editor: Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha), 1,2 B.1.351(beta), 1 and B.1.617.2 (delta) 3 variants.However, the B.1.1.529(omicron) variant harbors multiple mutations that can mediate immune evasion.We estimated the effectiveness of previous infection in preventing symptomatic new cases caused by omicron and other SARS-CoV-2 variants in Qatar.In this study, we extracted data regarding coronavirus disease 2019 (Covid-19) laboratory testing, vaccination, clinical infection data, and related demographic details from the national SARS-CoV-2 databases, which include all results of polymerase-chain-reaction (PCR) testing, vaccinations, and hospitalizations and deaths for Covid-19 in Qatar since the start of the pandemic.The effectiveness of previous SARS-CoV-2 infection in preventing reinfection was defined as the proportional reduction in susceptibility to infection among persons who had recovered from infection as compared with those who had not been infected. 4Previous SARS-CoV-2 infection was defined as a positive result on PCR assay at least 90 days before a new positive PCR finding. 4We used a test-negative, case-control study design to assess the effectiveness of previ-Downloaded from nejm.org

Referência(s)